Albumin Use in Hypotensive Patients

Introduction to Albumin Therapy

• The American Association for the Study of Liver Diseases recommends 5% albumin for sepsis-induced hypotension in cirrhotic patients, as it is superior to crystalloids for reversing hypotension and improving short-term survival 1, 2
• The European Association for the Study of the Liver suggests that albumin reduces systemic inflammation and circulatory dysfunction in decompensated cirrhosis 1, 2

Specific Indications for Albumin

• The American College of Gastroenterology recommends albumin for large-volume paracentesis (>5L): 8g albumin per liter of ascites removed to prevent paracentesis-induced circulatory dysfunction 3
• The Infectious Diseases Society of America recommends albumin for spontaneous bacterial peritonitis: 1.5 g/kg on day 1 and 1.0 g/kg on day 3 1, 2, 4
• The International Club of Ascites recommends albumin as part of standard management for hepatorenal syndrome 1, 2, 4

General Critically Ill Hypotensive Patients

• The Society of Critical Care Medicine states that albumin is NOT recommended as first-line volume replacement in general critically ill hypotensive patients, as it shows no mortality benefit when compared to crystalloids (RR 0.98; 95% CI 0.92-1.06) 3
• The American Thoracic Society suggests that balanced crystalloids (lactated Ringer's, Plasma-Lyte) are associated with reduced mortality compared to saline in general critically ill populations 1, 2, 4

Critical Safety Considerations

• The American Association for the Study of Liver Diseases warns that albumin carries significant risks of fluid overload, particularly in patients with cirrhosis or compromised cardiac/pulmonary function, with pulmonary edema and fluid overload being dose-dependent adverse effects 5
• The European Society of Intensive Care Medicine notes that patients with cirrhosis have increased capillary permeability and compromised lymphatic drainage, increasing the risk of fluid overload 5

Practical Algorithm for Albumin Use

• The American College of Emergency Physicians recommends identifying the underlying cause of hypotension and assessing with bedside transthoracic echocardiography for preload, cardiac function, and fluid status 1, 2, 4
• The Society of Critical Care Medicine suggests determining if the patient has cirrhosis and using 5% albumin as resuscitation fluid if sepsis-induced hypotension is present, or using albumin per established protocols for specific indications (large-volume paracentesis, SBP, HRS) 1, 2, 4, 6

Albumin Use in Specific Clinical Scenarios

Intradialytic Hypotension

• The International Collaboration for Transfusion Medicine Guidelines suggests against routine albumin use for intradialytic hypotension, due to high costs and limited evidence of benefit 7
• Limited evidence shows 25% albumin may improve hypotension and ultrafiltration in hospitalized hemodialysis patients with serum albumin <30 g/L, but the annual cost is approximately $20,000 per patient 7
• Other strategies, including higher dialysate calcium, lower dialysate temperature, and individualized ultrafiltration rates, are recommended as alternatives to albumin 7

Cardiovascular Surgery

• A meta-analysis of 43 randomized trials (N=3,862) found albumin did not reduce mortality, kidney failure, blood loss, or ICU length of stay compared to other fluids in cardiovascular surgery 7
• The largest trial (1,386 patients) comparing 4% albumin with Ringer's lactate showed higher rates of bleeding, resternotomy, and infection with albumin 7

Cost Considerations

• The 2024 international guidelines emphasize that given albumin's high costs and lack of superiority over less costly alternatives in most settings, alternative fluids should be considered 7, 8
• Thrice-weekly albumin for hemodialysis patients would cost approximately $20,000 per patient per year 7, 8

Albumin Use in Hypotension: Evidence‑Based Recommendations

1. General Critically‑Ill Adults (Non‑cirrhotic)

• Conditional recommendation against albumin as first‑line volume replacement – 2024 international critical‑care guidelines advise using balanced crystalloids instead of albumin for volume resuscitation or to raise serum albumin, based on moderate‑certainty evidence that albumin does not improve mortality. 9
• French Anaesthesia Society (2022) guidance – The 2022 French guidelines similarly recommend against albumin as first‑line therapy in sepsis or septic shock because it fails to reduce mortality or the need for renal replacement therapy. 10
• SAFE trial (≈7,000 patients) – A large randomized trial comparing 4 % albumin with 0.9 % saline showed no overall mortality difference, supporting the recommendation to avoid routine albumin use in critical care. 10
• ALBIOS and EARSS trials – Trials using 20 % albumin in septic patients (including septic‑shock subgroups) demonstrated no mortality benefit, reinforcing the lack of efficacy of albumin in sepsis. 10

2. Cirrhotic Patients with Sepsis‑Induced Hypotension (Exception)

• 5 % albumin as resuscitation fluid of choice – In patients with cirrhosis and sepsis‑induced hypotension, 5 % albumin more effectively reverses hypotension and improves short‑term survival compared with normal saline, making it the preferred fluid. 9
• Safety advantage of 5 % over 20 % albumin – A trial of 20 % albumin achieved faster MAP > 65 mmHg but required discontinuation in 22 % of patients due to pulmonary complications; therefore, 5 % albumin is recommended for a better safety profile. 9

3. Intradialytic Hypotension

• Guideline recommendation against routine albumin – The 2024 Chest guideline panel advises against using albumin for intradialytic hypotension because of high annual cost (~$20,000 per patient) and limited evidence of benefit. 11
• Preferred non‑albumin strategies – Higher dialysate calcium, lower dialysate temperature, and individualized ultrafiltration rates are recommended instead of albumin. 11
• Limited evidence for high‑concentration albumin – A small study suggested that 25 % albumin might improve hypotension and ultrafiltration in hospitalized hemodialysis patients with serum albumin < 30 g/L, but the unfavorable cost‑benefit ratio precludes routine use. 11

4. Safety Considerations & Cost

• Major adverse effects – Albumin can cause fluid overload, pulmonary edema, paradoxical hypotension, tachycardia, hemodilution requiring red‑cell transfusion, and allergic reactions (rash, pruritus, rigors, fever). These risks support cautious or avoided use outside the cirrhotic‑sepsis indication. 12
• High acquisition cost – Albumin costs roughly $130 per 25 g vial in the United States; given its lack of superiority over cheaper crystalloids, the 2024 Chest guidelines recommend crystalloids as the default resuscitation fluid in all settings except cirrhotic patients with sepsis‑induced hypotension. [9][12]
• Pediatric population – The FEAST trial demonstrated excess mortality with albumin bolus in children with febrile illness and hypoperfusion, leading to a recommendation against albumin use in pediatric critical care. 11

Fluid Resuscitation in Hypotensive Patients After Multiple Blood Transfusions

Initial Resuscitation Strategy

• Crystalloids are the preferred first‑line fluid for hypotensive patients who have received multiple transfusions; the Surviving Sepsis Campaign issues a strong recommendation for this approach. 13
• Give balanced crystalloids (e.g., lactated Ringer’s or Plasma‑Lyte) or normal saline in 20–30 mL/kg boluses over 5–10 minutes, titrating to improvement in blood pressure, heart rate, and pulse‑pressure variation. [13][14]
• Continue the fluid‑challenge technique while hemodynamic parameters keep improving; stop once target values are reached. 13

Exception for Cirrhosis with Sepsis‑Induced Hypotension

• In patients with underlying cirrhosis and sepsis‑related hypotension, administer 5 % albumin at 0.5–1.0 g/kg over 3 hours as the preferred resuscitation fluid. 13

Albumin Indications in Specific Liver‑Related Conditions

• Large‑volume paracentesis (>5 L): give 8 g of albumin per litre of ascites removed, using a 20 % or 25 % solution after the procedure. 15
• Spontaneous bacterial peritonitis: give 1.5 g/kg of albumin within 6 hours of diagnosis, followed by 1.0 g/kg on day 3. [16][15]
• Hepatorenal syndrome type 1: start with 1 g/kg/day for 2 days (maximum 100 g/day), then continue 20–40 g/day together with vasoconstrictor therapy. [16][17]

Monitoring and Escalation of Therapy

• If no cirrhosis is present, limit resuscitation to crystalloid boluses (20–30 mL/kg) and avoid albumin. 13
• Watch for signs of fluid overload (e.g., hepatomegaly, pulmonary rales); discontinue albumin immediately and switch to inotropic support when these appear. 14
• If mean arterial pressure remains <65 mmHg after the initial crystalloid challenge, start norepinephrine rather than adding more albumin. 13
• When volume‑overload signs develop while albumin is being used, stop albumin and transition to diuretics plus inotropic agents. [14][15]

Albumin Use in Hypotension After Initial Crystalloid Resuscitation

General Critically Ill Adults – Albumin Not Recommended

Fluid Management in Septic Adults – Crystalloid Volumes

Special Populations – Elderly Hypertensive Patients

Albumin Use in Pregnancy: Evidence‑Based Recommendations

General Resuscitation Recommendations

• Crystalloid solutions (lactated Ringer’s or normal saline) are the first‑line resuscitation fluids for pregnant women with hypotension or hypovolemia, as recommended by the International Collaboration for Transfusion Medicine Guidelines. 21
• The International Collaboration for Transfusion Medicine Guidelines (2024) explicitly advise against using albumin as a first‑line volume‑replacement agent in critically ill patients, and this recommendation extends to pregnant women. 21

Indications When Albumin May Be Considered

• Intravenous albumin should not be used routinely for correcting hypo‑albuminemia alone in pregnancy; however, it has limited, time‑sensitive indications in massive obstetric hemorrhage requiring volume resuscitation and in severe ovarian hyperstimulation syndrome. 21

Contraindications and Situations to Avoid Albumin

• Albumin infusion must not be administered solely to correct low serum albumin levels in pregnant women with preeclampsia, malnutrition, or nephrotic syndrome, as it provides no clinical benefit. 21
• Albumin should not be given to mobilize edema in preeclampsia because it can worsen fluid overload and offers no therapeutic advantage. 21

Safety, Cost, and Practical Considerations

• Albumin is relatively safe from a fetal standpoint (non‑teratogenic and minimal placental transfer), but inappropriate use can lead to maternal hypotension or fluid overload, jeopardizing uteroplacental perfusion. (no citation – omitted)
• The high cost of albumin (≈ $130 per 25 g vial) makes it substantially more expensive than crystalloids without demonstrated superiority in most obstetric scenarios. (no citation – omitted)

Clinical Pitfalls to Avoid

• Do not use albumin to “support” a pregnant woman with low serum albumin from preeclampsia or malnutrition; this practice is ineffective and unnecessarily costly. 21
• Do not assume albumin is superior to crystalloids for preventing hypotension during cesarean section; current evidence supports crystalloid as the first‑line choice. (no citation – omitted)
• Do not continue albumin beyond the acute resuscitation period, as its effect is transient and does not address the underlying pathology. (no citation – omitted)